Comparative Pharmacology
Head-to-head clinical analysis: DERMOTIC versus DESOXIMETASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMOTIC versus DESOXIMETASONE.
DERMOTIC vs DESOXIMETASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
Apply a thin film to affected skin areas twice daily.
None Documented
None Documented
Clinical Note
moderateDesoximetasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin."
Clinical Note
moderateDesoximetasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin."
Clinical Note
moderateDesoximetasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Terminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Desoximetasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin."